Development and validation of an in vitro method for prognostic diagnosis of patients with HER2-positive breast cancer

The HER2DX assay integrates tumor and immune-related biology to predict survival and pCR in HER2-positive breast cancer, addressing the need for comprehensive treatment guidance by using a multivariate score that includes tumor size, nodal status, and gene expression.

JP2024543736APending Publication Date: 2024-11-22リヴィール ゲノミクス エセエレ +4
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024537011
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-20
Filing Date
2022-12-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Current methods for treating HER2-positive breast cancer lack tools that integrate multiple variables such as tumor size, nodal status, hormone receptor expression, and molecular subtypes to guide therapy escalation or de-escalation, leading to suboptimal treatment decisions.

Method used

Development of a multivariate prognostic score, the HER2DX assay, which integrates tumor size, nodal staging, stromal tumor-infiltrating lymphocytes (TILs), intrinsic molecular subtypes, and expression of 27 genes to predict response to anti-HER2 therapy and survival benefit.

Benefits of technology

The HER2DX assay provides accurate estimates of recurrence risk and probability of achieving pathological complete response (pCR), guiding personalized treatment decisions and improving survival outcomes in HER2-positive breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543736000038
    Figure 2024543736000038
  • Figure 2024543736000039
    Figure 2024543736000039
  • Figure 2024543736000040
    Figure 2024543736000040
Patent Text Reader

Abstract

The present invention relates to an in vitro method for prognosing, predicting response to, and / or predicting survival benefit from, anti-HER2 therapy in patients with HER2+ breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the medical field. In particular, the present invention relates to an in vitro method for prognosing, predicting response to, and / or predicting survival benefit from, anti-HER2 therapy in patients with HER2+ breast cancer. [Background technology]

[0002] HER2-positive breast cancer is responsible for a significant proportion of deaths. Early (neo)adjuvant chemotherapy and trastuzumab (plus endocrine therapy in hormone receptor-positive disease) have consistently shown significant extension of survival. However, there is significant clinical and biological heterogeneity in HER2-positive disease, which affects patient prognosis and treatment outcomes.

[0003] Strategies to escalate or deescalate systemic therapy in early-stage HER2-positive breast cancer to improve survival outcomes and quality of life have been explored, such as reducing the number of chemotherapy cycles and duration of trastuzumab in patients who have not achieved pathological complete response (pCR) after neoadjuvant therapy, increasing HER2 blockade with pertuzumab or neratinib, or switching anti-HER2 therapy to trastuzumab emtansine. Despite these advances, most patients with early-stage HER2-positive breast cancer are treated with chemotherapy and trastuzumab alone.

[0004] In addition to tumor burden, several variables are associated with patient prognosis and / or treatment response in early-stage HER2-positive breast cancer. For example, the percentage of stromal tumor-infiltrating lymphocytes (TILs), hormone receptor status, and intrinsic molecular subtypes of breast cancer are all associated with response and / or survival. However, today, decisions regarding escalation or de-escalation of systemic therapy are made based on tumor size, nodal status, hormone receptor expression, and response to neoadjuvant therapy (i.e., pCR or not). Therefore, there is a need for a tool that can bring together these multiple variables to help guide therapy in early-stage HER2-positive breast cancer and perform better than any single feature. Summary of the Invention [Problem to be solved by the invention]

[0005] In 2020, the inventors reported HER2DX, which constructs a multivariate prognostic score in early-stage HER2-positive breast cancer that integrates information including tumor size and nodal staging, TILs, intrinsic molecular subtype, and expression of 13 individual genes, but the present invention aims to validate new signatures that can be used to improve the prognosis of patients with HER2+ breast cancer, predict response to anti-HER2 therapy, and / or predictive survival benefit from anti-HER2 therapy. [Means for solving the problem]

[0006] As explained above, the present invention relates to an in vitro method for prognosing, predicting response to anti-HER2 therapy, and / or predicting survival benefit from anti-HER2 therapy in patients with HER2+ breast cancer. In particular, the inventors of the present invention have developed an improved assay, called HER2DX assay, that uses gene expression of up to 27 genes (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and / or TCAP), optionally in combination with clinical features, for prognosing, or predicting response to anti-HER2 therapy in patients with HER2+ breast cancer. This means, in the context of the present invention, that any of the 27 genes identified above, preferably any combination containing between 2 and 27 genes, can be used to provide a prognosis for, predict response to, and / or predict survival benefit from, anti-HER2 therapy in patients with HER2+ breast cancer.

[0007] On the other hand, gene expression of up to four genes (CD86, FGFR2, ERBB3, and / or FA2H) is used to predict survival benefit from anti-HER2 therapy, which means in the context of the present invention that any of the four genes identified above, preferably any combination including between two and four genes, can be used to predict response to and / or predict survival benefit from anti-HER2 therapy.

[0008] In a preferred embodiment, the 27 gene variables included in the HER2DX supervised learning algorithm are divided into four gene expression signatures that track immune infiltration, tumor cell proliferation, luminal differentiation, and HER2 amplicon expression, and a single score is generated. The four gene expression signatures are:

[0009] HER2DX Risk Score (provides prognosis for patients with HER2+ breast cancer): Immune Signature (IGG) (14 genes): (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17). Tumor cell proliferation signature (PROLIF) (4 genes): (EXO1, ASPM, NEK2, and / or KIF23). Luminal Differentiation Signature (LUM) (5 genes): (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1). HER2 Amplicon Signature (HER2) (4 genes): (ERBB2, GRB7, STARD3, and / or TCAP).

[0010] Coefficients for the full HER2DX prognostic risk score model were as follows: LUM: -0.087, PROLIF: 0.129, HER2: 0.00, IGG: -0.328, T stage (T1 vs. T2–4): 0 vs. 0.431, N stage (N0 vs. N1): 0 vs. 1.151, N stage (N0 vs. N2–3): 0 vs. 1.58.

[0011] HER2DX pCR Probability Score (predicts response to anti-HER2 therapy): Immune Signature (IGG) (14 genes): (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17). Tumor cell proliferation signature (PROLIF) (4 genes): (EXO1, ASPM, NEK2, and / or KIF23). Luminal Differentiation Signature (LUM) (5 genes): (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1). HER2 Amplicon Signature (HER2) (4 genes): (ERBB2, GRB7, STARD3, and / or TCAP).

[0012] The coefficients for the HER2DX pCR probability score model are: LUM: -0.365. PROLIF: 0.374. HER2: 0.215. IGG: 0.184. T stage (T1 vs. T2-4): 0 vs. -0.630. N stage (N0 vs. N1-3): 0 vs. -0.251.

[0013] To validate these signatures, 434 HER2+ tumors from the Short-HER trial were used to train a prognostic risk model, and 268 cases from an independent cohort were used to validate the accuracy of the HER2DX risk score. Additionally, 116 cases treated with anti-HER2-based neoadjuvant chemotherapy were used to train a predictive model for pathological complete response (pCR), and two independent cohorts of 91 and 67 cases were used to validate the accuracy of the HER2DX pCR probability score.

[0014] HER2DX variables were associated with good outcome (i.e., immune and luminal) and poor outcome (i.e., proliferation, and tumor and nodal staging). In the independent cohort, the continuous HER2DX risk score was significantly associated with disease-free survival (DFS) (p=0.002), with a 5-year DFS of 95.3% (92.4%-98.2%) in the low-risk group. For the neoadjuvant pCR predictor training cohort, HER2DX variables were associated with pCR (i.e., immune, proliferation, and HER2 amplicon) and non-pCR (i.e., luminal, and tumor and nodal staging). In both independent test set cohorts, the continuous HER2DX pCR probability score was significantly associated with pCR (p<0.0001). A weak negative correlation was found between the two HER2DX scores (correlation coefficient -0.19).

[0015] The two HER2DX tests provide accurate estimation of recurrence risk and probability of achieving pCR in early HER2-positive breast cancer. Therefore, in conclusion, HER2DX is a novel classifier based on 27 gene expression and clinical features for clinical use in patients with early HER2-positive breast cancer. The assay optionally integrates clinical data and genomic data capturing tumor-related and immune-related biology to predict two different clinical endpoints, namely long-term survival and probability of achieving pCR. We validate two novel assays, one for survival and one for pCR prediction, using multiple data sets, thus providing a high level of technical and clinical validation. Interestingly, the HER2DX risk score and the HER2DX pCR probability score provide complementary information, providing the opportunity to better guide therapy through the use of both response and survival predictions.

[0016] In a preferred embodiment, 23 of the 27 genes (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1) are used to prognose patients with HER2+ breast cancer, and the 27 genes (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1) are used to prognose patients with HER2+ breast cancer. GKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and / or TCAP) were used to predict response to anti-HER2 therapy in patients with HER2+ breast cancer or to classify patients as responders or non-responders to anti-HER2 therapy.

[0017] Thus, a first embodiment of the present invention provides an in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising measuring the expression level of at least one gene selected from the group comprising: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 23 of the above mentioned genes, in a biological sample obtained from the patient, a. a statistically significant overexpression of at least one gene selected from the group comprising (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17) relative to a pre-established reference expression level, or any combination thereof comprising between 2 and 14 of the above genes, is indicative of a favorable prognosis; and / or b. A statistically significant overexpression of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four of the above genes, relative to a pre-established reference expression level is indicative of a poor prognosis; and / or c. A method in which a statistically significant overexpression of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between two and five of the above genes, relative to a pre-established reference expression level is indicative of a favorable prognosis.

[0018] A second embodiment of the invention relates to an in vitro method for prognosis of a patient suffering from HER2+ breast cancer, comprising measuring the expression level of at least one gene selected from the group comprising: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 of said genes, wherein a statistically significant overexpression of at least one gene selected from the group comprising: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 of said genes, relative to a pre-established reference expression level is indicative of a favorable prognosis.

[0019] A third embodiment of the present invention relates to an in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising measuring the expression level of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four of said genes, wherein a statistically significant overexpression of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four of said genes, relative to a pre-established reference expression level is indicative of a poor prognosis.

[0020] A fourth embodiment of the present invention relates to an in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising measuring the expression level of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 5 of said genes, wherein a statistically significant overexpression of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 5 of said genes, relative to a pre-established reference expression level is indicative of a favorable prognosis.

[0021] A fourth embodiment of the present invention provides an in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising measuring the expression level of at least one gene selected from the group comprising: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between 2 and 27 of said genes, in a biological sample obtained from the patient, a. a statistically significant overexpression of at least one gene selected from the group comprising (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 genes, relative to a pre-established reference expression level indicates that the patient is a responder patient to anti-HER2 therapy; and / or b. A statistically significant overexpression of at least one gene selected from the group including (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof including between two and four genes, relative to a pre-established reference expression level indicates that the patient is a responder patient to anti-HER2 therapy; and / or c. A statistically significant overexpression of at least one gene selected from the group including (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof including between two and five genes, relative to a pre-established reference expression level indicates that the patient is a non-responder to anti-HER2 therapy; and / or d. A method wherein a statistically significant overexpression of at least one gene selected from the group comprising (ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between two and four genes, relative to a pre-established reference expression level indicates that the patient is a responder patient to anti-HER2 therapy.

[0022] A fifth embodiment of the present invention provides a method for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or classifying patients as responders or non-responders to anti-HER2 therapy. The present invention relates to an in-vitro method comprising measuring an expression level of at least one gene selected from the group comprising (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 of the above genes, relative to a pre-established reference expression level in a biological sample obtained from the patient, wherein a statistically significant overexpression of at least one gene selected from the group comprising (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 of the above genes, relative to the pre-established reference expression level is indicative of the patient being a responder patient to anti-HER2 therapy.

[0023] A sixth embodiment of the present invention relates to an in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising measuring the expression level of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four of said genes, relative to a pre-established reference expression level, wherein a statistically significant overexpression of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four of said genes, relative to a pre-established reference expression level is indicative of the patient being a responder to anti-HER2 therapy.

[0024] A seventh embodiment of the present invention relates to an in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising measuring the expression level of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 5 of said genes, relative to a pre-established reference expression level, wherein a statistically significant overexpression of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 5 of said genes, relative to a pre-established reference expression level is indicative of the patient being a non-responder to anti-HER2 therapy.

[0025] An eighth embodiment of the present invention relates to an in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising measuring the expression level of at least one gene selected from the group comprising (ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between two and four of said genes, relative to a pre-established reference expression level, wherein a statistically significant overexpression of at least one gene selected from the group comprising (ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between two and four of said genes, relative to a pre-established reference expression level is indicative that the patient is a responder to anti-HER2 therapy.

[0026] A ninth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 23 genes, for prognosing patients suffering from HER2+ breast cancer.

[0027] A tenth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 genes, for prognosing patients suffering from HER2+ breast cancer.

[0028] An eleventh embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four genes, for prognosing patients suffering from HER2+ breast cancer.

[0029] A twelfth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between two and five genes, for prognosing patients suffering from HER2+ breast cancer.

[0030] A thirteenth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1, ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between 2 and 27 genes, for predicting response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0031] A fourteenth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or any combination thereof comprising between 2 and 14 genes, for predicting response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0032] A fifteenth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (EXO1, ASPM, NEK2, and / or KIF23), or any combination thereof comprising between two and four genes, for predicting response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or for classifying patients into responder or non-responder patients to anti-HER2 therapy.

[0033] A sixteenth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between two and five genes, for predicting response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0034] A seventeenth embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between two and four genes, for predicting response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0035] In a preferred embodiment, the invention further comprises identifying nodal status (pN1) and / or tumor staging (pT2-4), where identifying nodal status N1-3 and / or tumor status T2-4 indicates a poor prognosis or that the patient is a non-responder to anti-HER2 therapy.

[0036] In a preferred embodiment, the patient has HER2+ breast cancer.

[0037] In a preferred embodiment, the sample is selected from tissue, blood, serum or plasma.

[0038] In preferred embodiments, the anti-HER2 therapy is a drug selected from trastuzumab, pertuzumab, lapatinib, pyrotinib, poziotinib, tucatinib, neratinib, trastuzumab deruxtecan, SYD985, or ado-trastuzumab emtansine.

[0039] An eighteenth embodiment of the present invention relates to a group of genes consisting of only (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or any combination thereof comprising between 2 and 23 genes. The present invention relates to a kit comprising a reagent for measuring the expression level of a group of genes, preferably consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), (EXO1, ASPM, NEK2, and / or KIF23), or (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1).

[0040] A nineteenth embodiment of the present invention relates to a group of genes consisting of only (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and / or ESR1, ERBB2, GRB7, STARD3, and / or TCAP), or any combination thereof comprising between 2 and 27 genes, preferably or a kit comprising a reagent for measuring the expression level of a group of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or (EXO1, ASPM, NEK2, and / or KIF23), or (BCL2, DNAJC12, AGR3, AFF3, and / or ESR1), or (ERBB2, GRB7, STARD3, and / or TCAP).

[0041] A twentieth embodiment of the present invention relates to an anti-HER2 therapeutic agent or any pharmaceutical composition comprising the same, optionally with a pharma- ceutical acceptable excipient or carrier, for use in the treatment of a patient suffering from HER2+ breast cancer, wherein the patient has a high or low expression level of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and / or TNFRSF17), or (EXO1, ASPM, NEK2, and / or KIF23), or (ERBB2 , GRB7, STARD3, and / or TCAP), the patient being classified as a responder patient, whereby the anti-HER2 therapeutic is optionally selected from trastuzumab, pertuzumab, lapatinib, pyrotinib, poziotinib, tucatinib, neratinib, trastuzumab deruxtecan, SYD985, or ado-trastuzumab emtansine. In this sense, the present invention also relates to a method of treating a patient suffering from HER2+ breast cancer, comprising administering a therapeutically effective dose or amount of an anti-HER2 compound once the patient has been previously classified as a responder patient according to any of the above methods.

[0042] A twenty-first embodiment of the present invention relates to an in vitro method for predicting survival benefit from anti-HER2 therapy in a patient suffering from HER2+ breast cancer treated with anti-HER2 therapy, comprising measuring the expression level of at least one gene selected from the group comprising (CD86, FGFR2, ERBB3, and / or FA2H) in a biological sample obtained from the patient, wherein a statistically significant overexpression of at least one gene selected from the group comprising (CD86, FGFR2, ERBB3, and / or FA2H), or any combination thereof comprising between two and four genes, relative to a pre-established reference expression level is indicative of survival benefit of the patient suffering from HER2+ breast cancer treated with anti-HER2 therapy.

[0043] A twenty-second embodiment of the present invention relates to the in vitro use of at least one gene selected from the group comprising (CD86, FGFR2, ERBB3, and / or FA2H) for predicting survival benefit in patients with HER2+ breast cancer treated with anti-HER2 therapy.

[0044] A twenty-third embodiment of the present invention relates to a kit comprising a reagent for measuring the expression level of a group of genes consisting of only (CD86, FGFR2, ERBB3, and / or FA2H).

[0045] In particular, it is important to consider that although the method of the invention requires up to 23 or up to 27 genes, the invention provides strong data showing that a combination of at least two genes tracking luminal, proliferation, and immune pathways is a prognostic factor in early stage HER2+ breast cancer (Example 2.6), and that a combination of at least two genes tracking luminal, HER2 amplicon, proliferation, and immune signatures is a predictor of pathological complete response (pCR) (Example 2.7). Thus, in a preferred embodiment, the invention also relates to:

[0046] 1. An in vitro method for identifying a biomarker signature for prognosticating a patient suffering from HER2+ breast cancer, comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of expression of said two genes, wherein c) if a deviation of said combination score value is identified compared to a pre-established reference value, this indicates that said biomarker signature can be used for prognosticating a patient suffering from HER2+ breast cancer.

[0047] 1. An in vitro method for determining the prognosis of a patient suffering from HER2+ breast cancer, comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from the patient; and b) determining a combination score value by calculating a ratio of the expression of said two genes, wherein c) if a deviation of said combination score value is identified compared to a pre-established reference value, this indicates determining the prognosis of the patient suffering from HER2+ breast cancer.

[0048] 1. An in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from said patient; and b) determining a combined score value by calculating a ratio of the expression of said two genes, wherein said ratio is i. combining a first gene in an immune signature with a second gene in a tumor cell proliferation signature; or ii. combining a first gene in an immune signature with a second gene in a luminal differentiation signature; or iii. combining a first gene in a luminal differentiation signature with a second gene in a tumor cell proliferation signature; or iv. combining a first gene in an immune signature selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL with a second gene in an immune signature selected from the group consisting of CD27, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1; where: c) the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and d) A method wherein a deviation of said combined score value compared to a pre-established reference value is identified, which is indicative of a favorable prognosis.

[0049] 1. An in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising: a) measuring the expression levels of at least two genes selected from the gene combinations of Table 7A in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of expression of said two genes, wherein c) an identification of a deviation of said combination score value compared to a pre-established reference value is indicative of a favorable prognosis.

[0050] 1. An in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from said patient; and b) determining a combined score value by calculating a ratio of the expression of said two genes, wherein said ratio is i. combining a first gene in a tumor cell proliferation signature with a second gene in an immune signature; or ii. combining a first gene in a luminal differentiation signature with a second gene in an immune signature; or iii. combining a first gene included in a tumor cell proliferation signature with a second gene included in a luminal differentiation signature; or iv. combining a first gene in an immune signature selected from the group consisting of CD27, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1 with a second gene in an immune signature selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL; where: c) the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and d) A method wherein a deviation of said combined score value compared to a pre-established reference value is identified, which is indicative of a poor prognosis.

[0051] 1. An in vitro method for prognosticating a patient suffering from HER2+ breast cancer, comprising: a) measuring the expression levels of at least two genes selected from the gene combinations of Table 7B in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of expression of said two genes, wherein c) an identified deviation of said combination score value compared to a pre-established reference value is indicative of a poor prognosis.

[0052] 1. An in vitro method for prognosticating a patient with HER2+ breast cancer, comprising measuring the expression levels of a group of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and ESR1).

[0053] To identify biomarker signatures that predict response to anti-HER2 therapy in patients with HER2+ breast cancer or classify patients as responders or non-responders to anti-HER2 therapy 1. An in-vitro method comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of expression of said two genes, wherein c) if a deviation of said combination score value is identified compared to a pre-established reference value, this indicates that said biomarker signature can be used to predict response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or to classify patients into responder or non-responder patients to anti-HER2 therapy.

[0054] To predict response to anti-HER2 therapy in patients with HER2+ breast cancer or to classify patients as responders or non-responders to anti-HER2 therapy 1. An in-vitro method comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of the expression of said two genes, wherein c) if a deviation of said combination score value is identified compared to a pre-established reference value, this is indicative of a response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer.

[0055] 1. An in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying said patient as a responder or non-responder to anti-HER2 therapy, comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of the expression of said two genes, wherein said ratio is i. combining a first gene in an immune signature with a second gene in a luminal differentiation signature; or ii. combining a first gene included in a tumor cell proliferation signature with a second gene included in a luminal differentiation signature; or iii. combining a first gene in a HER2 amplicon signature with a second gene in an immune signature; or iv. combining a first gene in a HER2 amplicon signature with a second gene in a tumor cell proliferation signature; or v. Combining a first gene in a HER2 amplicon signature with a second gene in a luminal differentiation signature; or vi. Combining a first gene in an immune signature selected from the group consisting of IGKC, IGL, or LAX1 with a second gene in an immune signature selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17; or vii. A combination of a first gene included in a luminal differentiation signature selected from the group consisting of AFF3, BCL2, or DNAJC12 and a second gene included in a luminal differentiation signature selected from the group consisting of ESR1 or AGR3; or viii. combining ASPM as a first gene in the tumor cell proliferation signature with NEK2 as a second gene in the tumor cell proliferation signature; where: c) the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and the HER2 amplicon signature comprises a gene (ERBB2, GRB7, STARD3, or TCAP), and d) identification of a deviation of said combined score value compared to a pre-established reference value indicates that said patient suffering from HER2+ breast cancer may respond to anti-HER2 therapy.

[0056] 1. An in vitro method for predicting response to anti-HER2 therapy in a patient with HER2+ breast cancer or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising: a) measuring the expression levels of at least two genes selected from the gene combinations of Table 9A in a biological sample obtained from the patient; and b) determining a combination score value by calculating a ratio of expression of the two genes. wherein c) identifying a deviation of the combined score value compared to a pre-established reference value indicates that the patient suffering from HER2+ breast cancer may be responsive to anti-HER2 therapy.

[0057] 1. An in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying said patient as a responder or non-responder to anti-HER2 therapy, comprising: a) measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of the expression of said two genes, wherein said ratio is i. combining a first gene in a luminal differentiation signature with a second gene in an immune signature; or ii. combining a first gene in a luminal differentiation signature with a second gene in a tumor cell proliferation signature; or iii. combining a first gene in an immune differentiation signature with a second gene in a HER2 amplicon signature; or iv. combining a first gene in a tumor cell proliferation signature with a second gene in a HER2 amplicon signature; or v. Combining a first gene in a luminal differentiation signature with a second gene in a HER2 amplicon signature; or vi. Combining a first gene in an immune signature selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17 with a second gene in an immune signature selected from the group consisting of IGKC, IGL, or LAX1; or vii. A combination of a first gene included in a luminal differentiation signature selected from the group consisting of ESR1 or AGR3 and a second gene included in a luminal differentiation signature selected from the group consisting of AFF3, BCL2, or DNAJC12; or viii. combining a first gene in the tumor cell proliferation signature, NEK2, with a second gene in the tumor cell proliferation signature, ASPM; where: c) the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and the HER2 amplicon signature comprises a gene (ERBB2, GRB7, STARD3, or TCAP), and d) identification of a deviation of said combined score value compared to a pre-established reference value indicates that said patient suffering from HER2+ breast cancer may not respond to anti-HER2 therapy.

[0058] 1. An in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying said patient as a responder or non-responder to anti-HER2 therapy, comprising: a) measuring the expression levels of at least two genes selected from the gene combinations of Table 9B in a biological sample obtained from said patient; and b) determining a combination score value by calculating a ratio of expression of said two genes. wherein c) identification of a deviation of the combined score value compared to a pre-established reference value indicates that the patient suffering from HER2+ breast cancer may not respond to anti-HER2 therapy.

[0059] 1. An in vitro method for predicting response to anti-HER2 therapy in a patient with HER2+ breast cancer or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising measuring the expression levels of a group of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and TCAP).

[0060] In a preferred embodiment, the method further comprises identifying nodal status (pN1) and / or tumor staging (pT2-4), where identifying nodal status N1-3 and / or tumor status T2-4 indicates a poor prognosis or that the patient is a non-responder to anti-HER2 therapy.

[0061] In a preferred embodiment, the patient has HER2+ breast cancer.

[0062] In a preferred embodiment, the sample is selected from tissue, blood, serum or plasma.

[0063] In preferred embodiments, the anti-HER2 therapy is an agent selected from trastuzumab, pertuzumab, lapatinib, pyrotinib, poziotinib, tucatinib, neratinib, trastuzumab deruxtecan, SYD985, or ado-trastuzumab emtansine.

[0064] In vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) to identify a biomarker signature for prognosis in patients with HER2+ breast cancer.

[0065] In vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) for prognostication of patients with HER2+ breast cancer.

[0066] A method for prognosing a patient suffering from HER2+ breast cancer, comprising: detecting in vivo expression of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1); In vitro use, wherein a first gene is included in the immune signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the immune signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the luminal differentiation signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the immune signature and is selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL, and a second gene is included in the immune signature and CD2 7, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1, and wherein the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1).

[0067] 2. In vitro use of at least two genes selected from the gene combinations of Table 7A for prognosticating patients with HER2+ breast cancer.

[0068] A method for prognosing a patient suffering from HER2+ breast cancer, comprising: detecting in vivo expression of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1); In vitro use, wherein a first gene is included in a tumor cell proliferation signature and a second gene is included in an immune signature, or a first gene is included in a luminal differentiation signature and a second gene is included in an immune signature, or a first gene is included in a tumor cell proliferation signature and a second gene is included in a luminal differentiation signature, or a first gene is included in an immune signature, which is selected from the group consisting of CD27, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1, and a second gene is included in an immune signature. wherein the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1).

[0069] The in vitro use of at least two genes selected from the gene combinations of Table 7B for prognosticating patients suffering from HER2+ breast cancer.

[0070] In vitro use of a panel of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and ESR1) for prognostication of patients with HER2+ breast cancer.

[0071] 1. In vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) to identify a biomarker signature that predicts response to anti-HER2 therapy in patients with HER2+ breast cancer or classifies patients as responders or non-responders to anti-HER2 therapy.

[0072] 1. In vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0073] 2. The method of claim 1, further comprising: determining whether or not a patient with HER2+ breast cancer has a response to anti-HER2 therapy by using a marker of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) to predict response to anti-HER2 therapy in patients with HER2+ breast cancer or to classify patients as responders or non-responders to anti-HER2 therapy.In vitro use, wherein a first gene is included in the immune signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the tumor cell proliferation signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the HER2 amplicon signature and a second gene is included in the immune signature, or a first gene is included in the HER2 amplicon signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the HER2 amplicon signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the immune signature, which is selected from the group consisting of IGKC, IGL, or LAX1, and a second gene is included in the immune signature, which is selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17, or The first gene is included in the luminal differentiation signature, which is selected from the group consisting of AFF3, BCL2, or DNAJC12, and the second gene is included in the luminal differentiation signature, which is selected from the group consisting of ESR1 or AGR3, or the first gene is ASPM included in the tumor cell proliferation signature, and the second gene is NEK2 included in the tumor cell proliferation signature, and the immune signature is a combination of genes (CD27, CD79A, HLA-C, IGJ, IGKC, 10. In vitro use of a HER2 amplicon signature comprising a gene (ERBB2, GRB7, STARD3, or TCAP), said tumor cell proliferation signature comprising a gene (EXO1, ASPM, NEK2, or KIF23), said luminal differentiation signature comprising a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and said HER2 amplicon signature comprising a gene (ERBB2, GRB7, STARD3, or TCAP).

[0074] In vitro use of at least two genes selected from the gene combinations of Table 9A for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0075] 2. The method of claim 1, further comprising: determining whether or not a patient with HER2+ breast cancer has a response to anti-HER2 therapy by using a marker of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) to predict response to anti-HER2 therapy in patients with HER2+ breast cancer or to classify patients as responders or non-responders to anti-HER2 therapy.In vitro use, wherein a first gene is included in the luminal differentiation signature and a second gene is included in the immune signature, or a first gene is included in the luminal differentiation signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the immune signature and a second gene is included in the HER2 amplicon signature, or a first gene is included in the tumor cell proliferation signature and a second gene is included in the HER2 amplicon signature, or a first gene is included in the luminal differentiation signature and a second gene is included in the HER2 amplicon signature, or a first gene is included in the immune signature, which is selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17, and a second gene is included in the immune signature, which is selected from the group consisting of IGKC, IGL, or LAX1, or The first gene is included in the luminal differentiation signature, which is selected from the group consisting of ESR1 or AGR3, and the second gene is included in the luminal differentiation signature, which is selected from the group consisting of AFF3, BCL2, or DNAJC12; or the first gene is NEK2 included in the tumor cell proliferation signature, and the second gene is ASPM included in the tumor cell proliferation signature, and the immune signature is a combination of genes (CD27, CD79A, HLA-C, IGJ, IGKC, 10. In vitro use of a HER2 amplicon signature comprising a gene (ERBB2, GRB7, STARD3, or TCAP), said tumor cell proliferation signature comprising a gene (EXO1, ASPM, NEK2, or KIF23), said luminal differentiation signature comprising a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and said HER2 amplicon signature comprising a gene (ERBB2, GRB7, STARD3, or TCAP).

[0076] In vitro use of at least two genes selected from the gene combinations of Table 9B for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

[0077] In vitro use of a panel of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and TCAP) to predict response to anti-HER2 therapy in patients with HER2+ breast cancer or to classify patients into responders or non-responders to anti-HER2 therapy.

[0078] An anti-HER2 therapeutic agent or any pharmaceutical composition comprising the same, optionally comprising a pharma- ceutically acceptable excipient or carrier, for use in the treatment of a patient suffering from HER2+ breast cancer, said method comprising predicting a response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer, or classifying the patient as a responder or non-responder to anti-HER2 therapy, by following the method of the present invention.

[0079] 1. An anti-HER2 therapeutic agent or any pharmaceutical composition comprising same, optionally with a pharma- ceutically acceptable excipient or carrier, for use in the treatment of a patient suffering from HER2+ breast cancer, wherein said anti-HER2 therapeutic agent is optionally selected from trastuzumab, pertuzumab, lapatinib, pyrotinib, poziotinib, tucatinib, neratinib, trastuzumab deruxtecan, SYD985, or ado-trastuzumab emtansine.

[0080] The present invention also relates to a method of detecting a biomarker signature in a test sample from a patient with HER2+ breast cancer, comprising: a) contacting the test sample with a reagent specific for the biomarker; b) amplifying the biomarker to produce an amplification product in the test sample; and c) measuring the level by determining the level of the amplification product in the test sample.

[0081] In a preferred embodiment, the invention is a computer implemented invention, wherein the processing unit (hardware) and software is configured to a) receive expression level values ​​of any of the above mentioned biomarkers or signatures, b) process the received expression level values ​​to find substantial variations or deviations, and c) output the variation or deviation in expression levels through a terminal display.

[0082] In a preferred embodiment, the method of the invention further comprises determining or measuring the tumor stage and / or nodal status, for example by CT scan, ultrasound, and / or mammography.

[0083] For purposes of the present invention, the following terms are defined: The term "pre-established reference value", when referring to the level of the biomarker described in the present invention, refers to the geometric mean level of the five housekeeping genes, namely GAPD, PUM1, ACTB, RPLP0 and PSMC4, observed in patients. The "reference" value can be a threshold or cut-off value. Typically, the "threshold" or "cut-off value" can be determined experimentally, empirically or theoretically. The threshold value can also be arbitrarily selected based on existing experimental and / or clinical conditions, as will be recognized by those skilled in the art. The threshold value needs to be determined to obtain optimal sensitivity and specificity depending on the function of the test and the benefit / risk balance (clinical consequences of false positives and false negatives). Typically, the optimal sensitivity and specificity (and therefore the threshold value) can be determined using a receiver operating characteristic (ROC) curve based on experimental data. The term "variation or deviation" refers to values ​​above or below a pre-established reference value. The term "comprising" means including, without limitation, whatever precedes the word "comprising." Thus, use of the word "comprising" indicates that the listed elements are required or mandatory, but other elements are optional and may or may not be present. "Consisting of" means to include, by limitation, whatever precedes the phrase "consisting of." Thus, the phrase "consisting of" indicates that the recited elements are required or essential, and that no other elements may be present. A "pharmaceutically acceptable excipient or carrier" refers to an excipient that may optionally be included in a composition of the present invention and that causes no significant adverse toxicological effects to a patient. By "therapeutically effective dose or amount" of a composition is intended an amount that, when administered as described herein, results in a positive therapeutic response in a subject with HER2+ breast cancer. The exact amount required will vary from subject to subject, depending on the age and general condition of the subject, the severity of the condition being treated, the method of administration, etc. One of ordinary skill in the art can determine the appropriate "effective" amount in any individual case using routine experimentation based on the information provided herein. [Brief description of the drawings]

[0084] [Figure 1] FIG. 1 shows an overview of the different patient cohorts evaluated during the development and validation of HER2DX. [Diagram 2] Figure 1 shows survival outcomes of HER2DX low risk and HER2DX high risk groups in early stage HER2 positive breast cancer: (A) DRFS in Short-HER dataset, (B) DFS in Short-HER dataset, (C) OS in Short-HER dataset, (D) DFS in an independent combined validation dataset. [Diagram 3] FIG. 1 shows an overview of the variables included in the HER2DX assay and their association with each clinical endpoint. [Figure 4]Figure 1 shows survival curves based on CD86 expression and treatment arm. Low and high CD86 expression are defined by median values. Time is defined by months. DMFS96 is distant metastasis-free survival at 96 months. [Diagram 5] FIG. 1 is a Venn diagram depicting the number of combination scores (2-gene combination scores) significantly associated with survival outcome across the five datasets. [Figure 6] FIG. 1 is a Venn diagram depicting the number of combination scores (2-gene combination scores) significantly associated with pCR in the three datasets. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0085] The present invention is illustrated by the following examples, which are not intended to limit the scope of protection. EXAMPLES

[0086] Example 1. Materials and Methods Example 1.1. Study Design and Participants An overview of all cohorts evaluated is shown in Figure 1. Short-HER is an investigator-initiated, randomized, multicenter, phase 3 study aimed to assess the non-inferiority of adjuvant trastuzumab in combination with chemotherapy for 9 weeks versus 1 year. Briefly, women aged 18-75 years with surgically removed HER2+ breast cancer suitable for adjuvant chemotherapy were included. Women had to be node-positive or, if node-negative, had at least one of the following characteristics: tumor size >2 cm, grade 3, presence of lymphovascular invasion, Ki67 >20%, age ≤35 years, or hormone receptor negative. Patients with stage IIIB / IV disease were excluded. A total of 1254 patients with a performance status of 0 or 1 were randomly assigned to arm A or arm B between December 17, 2007 and October 6, 2013. Chemotherapy in arm A (long-term) consisted of adriamycin 60 mg / m 2 +Cyclophosphamide 600mg / m 2 or epirubicin 90 mg / m 2+Cyclophosphamide 600mg / m 2 every 3 weeks for 4 courses, followed by paclitaxel 175 mg / m 2 or docetaxel 100mg / m 2 The chemotherapy in arm B consisted of 4 cycles of trastuzumab every 3 weeks starting from the first taxane dose. 2 every 3 weeks for 3 courses, followed by 5-fluorouracil 600 mg / m 2 , epirubicin 60 mg / m 2 , cyclophosphamide 600mg / m 2 Patients received 3 cycles of 100 mg once every 3 weeks. Trastuzumab was started simultaneously with docetaxel and given weekly for 9 weeks. Radiotherapy and hormonal therapy, if indicated, were performed according to local standards. Median follow-up was 98.4 months.

[0087] PAMELA was an open-label, single-arm, phase 2 study conducted from October 22, 2013 to November 30, 2015, aimed at the ability of the PAM50 HER2-overexpression subtype to predict pCR at the time of surgery. Patients with stage I-IIIA HER2+ disease and performance status 0 or 1 received lapatinib (1000 mg daily) and trastuzumab for 18 weeks, and hormone receptor-positive patients additionally received letrozole (2.5 mg daily) or tamoxifen (20 mg daily) depending on menopausal status. Postoperative treatment was at the discretion of the treating physician. Median follow-up was 68.1 months.

[0088] The Hospital Clinic cohort and the University of Padua HER2+ cohort are consecutive series of patients with early stage HER2+ breast cancer and performance status 0 or 1 who were treated with trastuzumab-based neoadjuvant multiagent chemotherapy for 3 to 6 months followed by surgery from June 28, 2005 to September 26, 2020 (Hospital Clinic) and from February 23, 2009 to May 26, 2016 (University of Padua cohort) according to standard techniques. Adjuvant treatment was accomplished with trastuzumab for up to 1 year and with hormonal therapy for a minimum of 5 years in patients with hormone receptor-positive tumors. Radiotherapy was performed according to local guidelines. The median follow-up for the Hospital Clinic cohort and the University of Padua cohort was 43.1 and 49.9 months, respectively.

[0089] Three publicly available gene expression-based datasets containing clinical data and survival outcomes from patients with HER2-positive early breast cancer were explored. All data from The Cancer Genome Atlas (TCGA) dataset and METABRIC dataset were obtained from the cbioportal webpage. Data from SCAN-B dataset were obtained from GEO under accession number GSE81540. Gene expression data from TCGA and SCAN-B are based on RNA sequencing, whereas gene expression data from METABRIC are based on microarray. Patients in METABRIC did not receive anti-HER2 therapy, but no clear information on the type of locoregional and systemic therapy is available from these datasets.

[0090] Finally, we included two cohorts of consecutive patients with newly diagnosed HER2-negative breast cancer from hospital clinics and the SOLTI-1805 TOT-HER3 trial, a treatment opportunity trial. Only baseline pretreatment tumors were analyzed. There was no follow-up period.

[0091] The study was conducted in accordance with the Good Clinical Practice guidelines and the World Medical Association Declaration of Helsinki. Approval for the study was obtained from an independent ethical committee.

[0092] Example 1.2. Tumor Sample Procedure In the IDIBAPS Translational Genomics and Targeted Therapies in Solid Tumors, gene expression assays were performed on tumor samples from the Short-HER, PAMELA, University of Padua cohort and Barcelona Hospital Clinic cohort. Using a minimum of approximately 125 ng of total RNA, the expression of 185 breast cancer-related genes and five housekeeping genes (GAPD, PUM1, ACTB, RPLP0, and PSMC4) was measured using the nCounter platform (Nanostring Technologies, Seattle, USA). Finally, TILs in Short-HER were assessed on single hematoxylin-eosin stained slides and stromal TILs were scored according to predefined criteria.

[0093] Example 1.3. HER2DX Gene Signature HER2DX is based on four distinct gene signatures containing 27 genes that capture various biological processes including immune infiltration, tumor cell proliferation, luminal differentiation, and expression of the HER2 amplicon. The immune signature selected for HER2DX was a 14-gene immunoglobulin (IGG) module (i.e., CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, and TNFRSF17) previously identified by unsupervised clustering of human breast tumors. The IGG signature had previously shown strong independent prognostic value in a large breast cancer dataset in which patients had not received adjuvant systemic therapy. The other three gene signatures were identified from unsupervised clustering of the Short-HER HER2-positive dataset using data from 185 breast cancer-associated genes. The selected genes were derived from highly correlated gene clusters (correlation coefficients >0.80), the tumor cell proliferation signature included four genes (i.e., EXO1, ASPM, NEK2, and KIF23), the luminal differentiation signature included five genes (i.e., BCL2, DNAJC12, AGR3, AFF3, and ESR1), and the HER2 amplicon signature included four genes located on chromosome 17q11-12 (i.e., ERBB2, GRB7, STARD3, and TCAP). For each signature, the mean gene expression was calculated for each patient.

[0094] Example 1.4. Outcome The co-primary objective of this study was to derive and validate two independently trained HER2DX scores: a prognostic risk score and a pCR probability score. In the prognostic training dataset (i.e., Short-HER), the survival endpoint was DRFS, calculated as the time between randomization and distant recurrence or death before recurrence. In the validation prognostic dataset, due to data availability, the survival endpoint was DFS, calculated as the time between randomization and any of the following events: local, regional, and distant recurrence, contralateral breast cancer excluding in situ carcinoma, other second invasive primary cancer, death before recurrence or before second primary cancer, whichever occurred first. In all neoadjuvant datasets, pCR at the time of surgery was defined as the absence of invasive tumor cells in the breast and axilla.

[0095] Secondary objectives were: 1) to describe the clinicopathological characteristics of HER2DX risk groups, 2) to explore in-silico the association between HER2DX risk score and overall survival (OS) in a publicly available dataset of HER2-positive early breast cancer, and 3) to assess ERBB2 mRNA levels to predict HER2 status according to ASCO / CAP guidelines.

[0096] Example 1.5. Development and validation of the HER2DX risk score 434 patients enrolled in the Short-HER trial were used as the training dataset. Patient samples in the training dataset were split into a training set (67% of samples) and a test set (the remaining 33% of samples) balanced for distant recurrence-free survival (DRFS) events and treatment arm. Prognostic models of various feature sets were compared by the C-index, an index of rank concordance for survival data. These feature sets were evaluated by Monte Carlo cross-validation (MCCV) with 100 iterations. Cox proportional hazards models were fitted with ridge regression or elastic net at each training iteration and evaluated on the MCCV test set.

[0097] A single cut-off from the final HER2DX risk score was chosen to divide patients into low-risk and high-risk groups. The criterion for choosing this cut-off was that the low-risk group must have the lower limit of the 95% confidence interval of the DRFS estimate above 90% at 3, 5, and 7 years. The final HER2DX risk score was tested in 268 patients from the validation dataset as a continuous variable and using prespecified cut-offs. The validation dataset consisted of patients from the Barcelona Hospital Clinic HER2-positive cohort (n=147), PAMELA (n=84), and the Padua University cohort (n=37). The median follow-up time for the validation dataset was 51.0 months.

[0098] To further evaluate the prognostic value of the HER2DX risk score, the HER2DX algorithm was evaluated in-silico across three publicly available datasets of patients with early-stage HER2-positive breast cancer (i.e., TCGA, METABRIC, and SCAN-B). Due to known technical biases between different genomic platforms, HER2DX risk models were explored both with and without clinical variables (i.e., tumor staging and nodal staging) as continuous variables.

[0099] Example 1.6. Development and validation of a HER2DX pCR probability score 116 patients with early stage HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy at the Barcelona Hospital Clinic were used as a training dataset for the HER2DX pCR Probability Score. Patient samples in the training dataset were split into a training set (67% of samples) and a test set (the remaining 33% of samples), balanced for pCR status. A logistic regression model was fitted with ridge regression at each training iteration and evaluated on the MCCV test set. Two cutoffs based on tertiles in the training dataset were defined to divide patients into three groups: low, intermediate, and high pCR probability. The final HER2DX pCR Probability Score was tested in 158 patients from two validation datasets, as a continuous variable and using prespecified cutoffs. The first validation dataset consisted of 67 patients treated with trastuzumab-based chemotherapy from the University of Padua cohort (n=37) and the Barcelona Hospital Clinic cohort (n=30). The second validation dataset consisted of 91 patients treated with neoadjuvant lapatinib and trastuzumab without chemotherapy from the PAMELA study.

[0100] Example 1.7. HER2DX ERBB2 mRNA Expression Assay A cohort of 637 patients with primary invasive breast cancer with HER2 status known according to ASCO / CAP guidelines was evaluated using the HER2DX assay and used as a training dataset to predict clinical HER2 status. The dataset consisted of 203 patients with newly diagnosed early stage HER2-negative breast cancer in hospital clinics and 434 patients from the Short-HER HER2-positive cohort. Receiver operating curve and Youden index analysis yielded optimal cut-offs of ERBB2 expression predictive of HER2 clinical status (positive vs. negative). The optimal ERBB2 cut-offs were validated in an independent cohort of 353 HER2-negative and HER2+ cases from the SOLTI-1805 TOT-HER3 HER2-negative study (n=85), the Barcelona Hospital Clinic HER2-positive cohort (n=147), PAMELA (n=84), and the University of Padua cohort (n=37).

[0101] Example 1.8. Summary statistical procedure For descriptive purposes, 3-, 5-, and 7-year estimates of DRFS or DFS were calculated by Kaplan-Meier. Univariate and multivariate Cox proportional hazards regression analyses were used to investigate the association of each variable with survival outcomes. Likelihood ratio values ​​(χ 2 ) was used to measure and compare the relative amount of prognostic information. Categorical variables were expressed as numbers (%), and χ 2 Comparisons were made by the ANOVA or Fisher's exact test. Logistic regression analysis was performed to investigate the association of each variable with pCR. C-index and receiver operating characteristic (ROC) curves were used as performance measures. The significance level was set at a two-sided alpha point of 0.05. R version 4.0.5 was used for all statistical analyses.

[0102] Example 1.9. Funder Role The study was designed and carried out by researchers from the University of Padua, the Hospital Clinic, and Reveal Genomics. All authors had full access to all data in the study and have final responsibility for the decision to submit for publication.

[0103] Example 2. Results Example 2.1. Development and validation of the HER2DX risk score Clinicopathologic and gene expression data were available for 434 of 1254 patients (35%) in the Short-HER study to construct the prognostic model (Table 1).

[0104] TIFF2024543736000001.tif156170

[0105] The mean age was 55.4 years, and most of the tumors were 2 cm or less (T1 stage), node negative (N0 stage), hormone receptor positive, and histological grade 3. In this cohort, our previous study showed that the best prognostic model integrated tumor size, node status, TIL, and the main biology associated with the four intrinsic subtypes. Based on these previous findings, we redeveloped the HER2DX risk score based on tumor stage (T1 vs. T2 vs. T3-4) and node stage (N0 vs. N1 vs. N2-3), along with four gene expression-based signatures tracking immune infiltration, tumor cell proliferation, HER2 amplicon expression, and tumor cell luminal differentiation. To capture immune infiltration, we chose our previously described IGG signature, which showed strong prognostic value in early breast cancer. HER2DX variables were associated with good outcome (i.e., immune / IGG and luminal) and poor outcome (i.e., proliferation, and tumor staging and nodal staging) when examined in univariate analysis. Overall, the predictive performance (C-index) of the HER2DX risk score in Short-HER was 0.74, which was very similar to the C-index (0.72) of our previously reported HER2DX risk model based on 17 different variables. Of note, the predictive performance of HER2DX did not improve when we tried to add more variables to the current HER2DX risk model, including TIL, intrinsic subtype, and individual genes.

[0106] HER2DX, measured as a continuous variable, was significantly associated with distant recurrence-free survival (DRFS) in the Short-HER 434-patient dataset (p<0.001). To select clinically relevant cutoffs, the low-risk group was defined as patients with 3-, 5-, and 7-year DRFS with the lower limit of the 95% confidence interval (CI) above 90%. With this selected cutoff, 49.8% (n=216) of patients were identified as low-risk. The 3-, 5-, and 7-year DRFS of the low-risk population were 97.7% (95%CI 95.7-99.7), 95.3% (95%CI 92.5-98.2), and 94.0% (95%CI 90.6-97.4), respectively (Figure 2A). The 3-year DRFS, 5-year DRFS, and 7-year DRFS of the high-risk group were 90.4% (95%CI 86.5-94.4), 84.3% (95%CI 79.6-89.3), and 78.6% (95%CI 73.2-84.5), respectively. The hazard ratios (HRs) of DRFS, DFS, and OS between the low-risk and high-risk groups were 0.26 (95%CI 0.1-0.5), 0.51 (95%CI 0.3-0.8), and 0.45 (95%CI 0.2-0.9), respectively (Figures 2A-C). With regard to clinicopathological characteristics, the two risk groups showed statistically significant differences in terms of TILs, nodal status, tumor size, and intrinsic subtype (Table 1).

[0107] An independent assessment of the HER2DX score was performed using a dataset of 268 patients with early HER2-positive disease derived from the combined cohorts of the three neoadjuvant studies (scores were determined on pretreatment samples before starting neoadjuvant therapy, Table 2 ).

[0108] TIFF2024543736000002.tif152170

[0109] The evaluation dataset consisted of 147 patients from the Hospital Clinic, 84 of 151 (56%) from PAMELA, and 37 patients from the University of Padua cohort. All patients received chemotherapy and 1 year of trastuzumab, 84 of 268 patients (31%) received dual HER2 blockade with lapatinib and trastuzumab for 4.5 to 6.0 months, and 66 of 268 patients (25%) received 4 to 6 cycles of neoadjuvant pertuzumab. Despite heterogeneity in systemic therapy, there were no significant differences in DFS across the four cohorts or between patients treated with trastuzumab alone versus dual HER2 blockade.

[0110] In an independent prognostic dataset, the HER2DX score as a continuous variable was significantly associated with DFS (HR 1.03, 95% CI 1.0-1.1, p=0.002). In this dataset, there was a 30% increase in hazard for the event for every 10-unit increase (from 0 to 100) in the HER2DX risk score. According to prespecified cutoffs, the HER2DX low-risk group had a longer DFS than the high-risk group (HR 0.21, 95% CI 0.1-0.6, p-value=0.005) (Figure 2B). The 5-year DFS in the HER2DX low-risk and HER2DX high-risk groups was 95.3% (95% CI 92.4-98.2) and 84.0% (79.6-89.3), respectively. The 7-year DFS in the HER2DX low-risk and HER2DX high-risk groups was 93.9% (95% CI 90.6-97.4) and 78.6% (73.2-84.5), respectively. The C-index of the HER2DX risk score was 0.73 for all patients.

[0111] To further explore the prognostic value of the HER2DX risk score, data were obtained from three publicly available breast cancer datasets (i.e., TCGA, METABRIC, and SCAN-B) that contain clinical data, overall survival (OS) outcomes, and gene expression data for a total of 810 patients with early-stage HER2-positive breast cancer. The HER2DX algorithm was applied in each dataset both with and without clinical features (i.e., tumor staging and nodal staging) (Table 3).

[0112] TIFF2024543736000003.tif94170

[0113] Across all public datasets examined, a statistically significant association was observed between the HER2DX risk score as a continuous variable and OS. Overall, these in-silico results support the strong prognostic value of HER2DX.

[0114] Example 2.2. Development and validation of a HER2DX pCR probability score To build a predictive model, the HER2DX assay was evaluated in pre-treatment tumors from 120 patients with early-stage HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy (Table 4).

[0115] TIFF2024543736000004.tif158170

[0116] The mean age was 55.4 years (SD 10.2), and most of the tumors were 2 cm or less (T1 stage), node negative (N0 stage), hormone receptor positive, and histological grade 3. Four gene signatures (i.e., HER2 amplicon, immune / IGG, luminal, and proliferation) and two clinical variables (i.e., tumor staging and node staging) were used to train the HER2DX pCR probability score. The HER2DX variables were associated with pCR (i.e., immune / IGG and proliferation) and non-pCR (i.e., luminal, and tumor staging and node staging). Overall, the predictive performance (AUC) of the HER2DX pCR probability score in the training dataset was 0.81.

[0117] An independent validation of the HER2DX pCR Probability Score was performed using two cohorts of 97 and 67 patients with early HER2-positive disease treated with anti-HER2-based neoadjuvant therapy (scores were determined at baseline before starting neoadjuvant therapy, Table 5).

[0118] TIFF2024543736000005.tif149170

[0119] In both cohorts, the HER2DX pCR Probability Score as a continuous variable was found to be statistically significantly associated with pCR (p<0.001). Overall, the predictive performance (AUC) of the HER2DX pCR Probability Score in the PAMELA study and the trastuzumab-based chemotherapy cohorts was 0.80 and 0.77, respectively. As expected, statistically significant differences in pCR rates were observed across the three response groups (i.e., defined by the tertiles determined in the training dataset) (Table 6).

[0120] TIFF2024543736000006.tif53170

[0121] Example 2.3. Relationship between both HER2DX scores To determine the similarity (or lack thereof) between both HER2DX scores, the combined HER2-positive dataset including Short-HER (n=434) and the validation prognostic dataset (n=268) was evaluated. Overall, the correlation coefficient for both HER2DX scores was weak (i.e., -0.19). In patients with HER2DX low risk, 46.3% (163 of 352) were identified as having a HER2DX high probability of pCR and 53.7% (189 of 352) were identified as having a HER2DX low / intermediate probability of pCR. In patients with HER2DX high risk, 33.1% (116 of 350) were identified as having a HER2DX high probability of pCR and 66.9% (234 of 350) were identified as having a HER2DX low / intermediate probability of pCR.

[0122] Example 2.4. HER2DX ERBB2 mRNA Expression Assay ERBB2 mRNA expression within HER2-positive breast cancer may help identify patients with high response to anti-HER2 therapy, including T-DM1. In addition, ERBB2 mRNA expression may help identify HER2 status according to ASCO / CAP guidelines. To construct an ERBB2 mRNA expression assay to track clinical HER2 status, we combined a Short-HER HER2-positive cohort (n=434) with a HER2-negative cohort (n=203) of patients newly diagnosed with early stage breast cancer at a hospital clinic. Overall, the mean ERBB2 expression (in binary logarithms) in HER2-negative and HER2-positive disease was -2.01 and 1.24 (6.5-fold difference), respectively. The ROC AUC of ERBB2 expression to predict clinical HER2 status was 0.97 with a sensitivity of 90% and a specificity of 98%. Using Youden analysis, an optimal cutoff of -0.98 was identified. 3.4% of clinically defined HER2-negative cases were identified as ERBB2 positive by mRNA, and 9.7% of clinically defined HER2-positive cases were identified as ERBB2 negative / low.

[0123] The optimal cutoff for predicting HER2 status was tested in an independent dataset of 85 HER2-negative and 268 HER2-positive cases (Figure 1). Overall, the mean ERBB2 expression (in binary logarithms) in HER2-negative and HER2-positive disease was -2.17 and 0.96 (a 6.3-fold difference), respectively. The ROC AUC of ERBB2 expression predicting clinical HER2 status was 0.96 with a sensitivity of 84% and a specificity of 100%. No HER2-negative cases were identified as ERBB2-positive, and 16.4% of HER2-positive cases were identified as ERBB2-negative / low.

[0124] Example 2.5. Interactions between four individual genes (as continuous variables) and treatment arm (9 weeks vs. 1 year) on DMFS at 96 months A total of four genes (i.e., CD86, FA2H, FGFR2, and ERBB3) were found to be associated with trastuzumab benefit in terms of DMFS depending on the duration of treatment (i.e., 1 year vs. 9 weeks). Low CD86 expression (as a continuous variable) was found to be associated with greater benefit when patients were treated for 1 year compared to 9 weeks (CD86 * arm, 9 weeks vs. 1 year of trastuzumab treatment, hazard ratio = 0.350, p-value for interaction = 0.0017). Low FA2H expression (as a continuous variable) was found to be associated with greater benefit when patients were treated for 1 year compared with 9 weeks (FA2H * arm, 9 weeks vs. 1 year of trastuzumab treatment, hazard ratio = 0.65, p-value for interaction = 0.046). High FGFR2 expression (as a continuous variable) was found to be associated with greater benefit when patients were treated for 1 year compared with 9 weeks (FGFR2 * arm, 9 weeks vs. 1 year of trastuzumab treatment, hazard ratio = 1.68, p-value for interaction = 0.027). Finally, high ERBB3 expression (as a continuous variable) was found to be associated with greater benefit when patients were treated for 1 year compared to 9 weeks (ERBB3 * arm, 9 weeks vs. 1 year of trastuzumab treatment, hazard ratio for DMFS96 = 1.99, p-value for interaction = 0.035).

[0125] Example 2.6. Combination of at least two genes tracing luminal, proliferation, and immune pathways is a prognostic factor in early stage HER2+ breast cancer The HER2DX risk score of the HER2DX assay consists of 23 genes (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and ESR1) and is used to predict prognosis in patients with HER2-positive (HER2+) breast cancer. The 23 genes belong to one of three gene expression signatures: luminal differentiation signature (n=5 genes), tumor cell proliferation signature (n=4), and immune signature (n=14).

[0126] The prognostic value of gene pairs (i.e., combinations of two genes) included in the three signatures was evaluated across five different datasets of patients with early stage HER2+ breast cancer, including: 1) The Short-HER dataset using distant metastasis-free survival (DMFS) as the survival endpoint: 434 patients with HER2+ breast cancer treated with adjuvant anti-HER2 therapy in the context of the Short-HER phase III clinical trial. 2) The Short-HER dataset using overall survival (OS) as the endpoint: 434 patients with HER2+ breast cancer treated with adjuvant anti-HER2 therapy in the context of the Short-HER phase III clinical trial. 3) TCGA dataset using OS as the endpoint: 164 patients with HER2+ breast cancer. 4) The METABRIC dataset using OS as an endpoint: 236 patients with HER2+ breast cancer. 5) SCAN-B dataset using OS as the endpoint: 378 patients with HER2+ breast cancer.

[0127] For each gene pair, a combination score was determined by calculating the ratio of expression of the two genes as follows: Combination score = gene 1 mRNA level (log2 value) - gene 2 mRNA level (log2 value).

[0128] The prognostic significance of each combined score was examined using univariate Cox models for DMFS and OS. As proof of concept, several pairs were identified that were significantly associated with prognosis in two or more datasets (Figure 5 and Table 7).

[0129] TIFF2024543736000007.tif222170TIFF2024543736000008.tif238170TIFF20245437360 00009.tif238170TIFF2024543736000010.tif238170TIFF2024543736000011.tif236170

[0130] TIFF2024543736000012.tif222170TIFF2024543736000013.tif233170TIFF2024543736000014.tif23317 0TIFF2024543736000015.tif233170TIFF2024543736000016.tif233170TIFF2024543736000017.tif68170

[0131] The combination scores showing good prognosis represent various combinations of the three signatures (i.e., immune-proliferation, immune-luminal, luminal-proliferation, and immune-immune). Specifically, 45% (n=35) of the combination scores are pairs composed of genes from the immune-proliferation signature, 10% (n=8) are pairs composed of genes from the immune-luminal signature, and 4% (n=3) are pairs composed of genes from the luminal-proliferation signature (Table 8). The combination scores showing poor prognosis represent various combinations of the three signatures (i.e., proliferation-immune, luminal-immune, proliferation-luminal, and immune-immune). Specifically, 45% (n=35) of the combination scores were pairs composed of genes from the proliferation-immune signature, 10% (n=8) were pairs composed of genes from the luminal-immune signature, and 4% (n=3) were pairs composed of genes from the proliferation-luminal signature (Table 8).

[0132] TIFF2024543736000018.tif42170

[0133] Example 2.7. Two-gene combinations tracking luminal signature, HER2 amplicon signature, proliferation signature, and immune signature are predictive of pathological complete response (pCR) The HER2DX pCR score of the HER2DX assay consists of 27 genes (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and TCAP) and predicts pCR in patients with HER2-positive (HER2+) breast cancer after anti-HER2-based neoadjuvant systemic therapy. The 27 genes belonged to one of four gene expression signatures: luminal differentiation signature (n=5 genes), HER2 amplicon signature (n=4), tumor cell proliferation signature (n=4), and immune signature (n=14).

[0134] The association of gene pairs (i.e., combinations of two genes) included in the four gene expression signature was evaluated across three different datasets of patients with early-stage HER2+ breast cancer treated with anti-HER2-based neoadjuvant systemic therapy, including: 1) Cohort 1, 117 patients with HER2+ breast cancer treated with anti-HER2-based neoadjuvant chemotherapy at the Barcelona Hospital Clinic. 2) Cohort 2, 88 patients who received neoadjuvant trastuzumab and lapatinib without chemotherapy in the context of the PAMELA phase II clinical trial. 3) Cohort 3, 67 patients with HER2+ breast cancer treated with anti-HER2-based neoadjuvant chemotherapy at the Barcelona Hospital Clinic (n=30) and the University of Padua (n=37).

[0135] For each gene pair, a combination score was determined by calculating the ratio of expression of the two genes as follows: Combination score = gene 1 mRNA level (log2 value) - gene 2 mRNA level (log2 value)

[0136] The ability of each combination score to predict pCR was tested using univariate logistic regression models for pCR. As proof of concept, several pairs were identified that were significantly associated with predicting response (pCR) in two or more data sets (Figure 6 and Table 9).

[0137] TIFF2024543736000019.tif225170TIFF2024543736000020.tif236170TIFF2024543736000021.tif236170TIFF2024543736000022.tif236170TIFF2024543736000023.tif236170TIFF2024543736000024.tif236170TIFF2024543736000025.tif236170TIFF2024543736000026.tif236170TIFF2024543736000027.tif184170

[0138] TIFF2024543736000028.tif224170TIFF2024543736000029.tif238170TIFF2024543736000030.tif238170TIFF2024543736000031.tif238170TIFF2024543736000032.tif238170TIFF2024543736000033.tif238170TIFF2024543736000034.tif238170TIFF2024543736000035.tif238170TIFF2024543736000036.tif190170

[0139] The combination scores, predictors of pCR, represent various combinations of the four signatures (i.e., immune-luminal, proliferation-luminal, HER2-immune, HER2-proliferation, HER2-luminal, immune-immune, luminal-luminal, proliferation-proliferation). Specifically, 48% (n=70) were pairs composed of genes from the immune-luminal signature, 14% (n=20) were pairs composed of genes from the proliferation-luminal signature, 6% (n=8) were pairs composed of genes from the HER2-immune signature, 8% (n=12) were pairs composed of genes from the HER2-proliferation signature, and 14% (n=20) were pairs composed of genes from the HER2-luminal signature (Table 10). The combination scores, predictive of lack of pCR, represent various combinations of the four signatures (i.e., luminal-immune, luminal-proliferative, immune-HER2, proliferation-HER2, luminal-HER2, immune-immune, luminal-luminal, and proliferation-proliferative). Specifically, 48% (n=70) were pairs composed of genes from the luminal-immune signature, 14% (n=20) were pairs composed of genes from the luminal-proliferative signature, 6% (n=8) were pairs composed of genes from the immune-HER2 signature, 8% (n=12) were pairs composed of genes from the proliferation-HER2 signature, and 14% (n=20) were pairs composed of genes from the luminal-HER2 signature (Table 10).

[0140] TIFF2024543736000037.tif46170

Claims

1. 1. An in vitro method for identifying a biomarker signature that is prognostic for a patient with HER2+ breast cancer, comprising: a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c. A method wherein a deviation of said combined score value compared to a pre-established reference value is identified, indicating that said biomarker signature can be used to provide a prognosis for patients with HER2+ breast cancer.

2. a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c) The in vitro method for prognosing a patient suffering from HER2+ breast cancer according to claim 1, wherein a deviation of the combined score value compared to a pre-established reference value is identified, which indicates prognosis of the patient suffering from HER2+ breast cancer.

3. a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; wherein the ratio is i. combining a first gene in an immune signature with a second gene in a tumor cell proliferation signature; or ii. combining a first gene in an immune signature with a second gene in a luminal differentiation signature; or iii. combining a first gene included in a luminal differentiation signature with a second gene included in a tumor cell proliferation signature; or iv. combining a first gene in an immune signature selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL with a second gene in an immune signature selected from the group consisting of CD27, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1; where: c. the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and d. An in vitro method for prognosing a patient suffering from HER2+ breast cancer according to claim 1 or 2, wherein a deviation of said combined score value compared to a pre-established reference value is identified as indicative of a favorable prognosis.

4. a. measuring the expression level of at least two genes selected from the gene combinations of Table 7A in a biological sample obtained from said patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c) An in vitro method for prognosing a patient suffering from HER2+ breast cancer according to any one of claims 1 to 3, wherein a deviation of said combined score value compared to a pre-established reference value is identified which is indicative of a good prognosis.

5. a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; wherein the ratio is i. combining a first gene included in a tumor cell proliferation signature with a second gene included in an immune signature; or ii. combining a first gene included in the luminal differentiation signature with a second gene included in the immune signature; or iii. combining a first gene included in a tumor cell proliferation signature with a second gene included in a luminal differentiation signature; or iv. combining a first gene in an immune signature selected from the group consisting of CD27, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1 with a second gene in an immune signature selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL; where: c. the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and d. An in vitro method for prognosing a patient suffering from HER2+ breast cancer according to claim 1 or 2, wherein a deviation of said combined score value compared to a pre-established reference value is identified, which is indicative of a poor prognosis.

6. a. measuring the expression level of at least two genes selected from the gene combinations of Table 7B in a biological sample obtained from said patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c) An in vitro method for prognosing a patient suffering from HER2+ breast cancer according to any one of claims 1, 2 and 5, wherein a deviation of said combined score value compared to a pre-established reference value is identified, which is indicative of a poor prognosis.

7. 7. An in vitro method for prognosticating a patient suffering from HER2+ breast cancer according to any one of claims 1 to 6, comprising measuring the expression levels of a group of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and ESR1).

8. 1. An in vitro method for identifying a biomarker signature that predicts response to anti-HER2 therapy in a patient with HER2+ breast cancer or classifies the patient as a responder or non-responder to anti-HER2 therapy, comprising: a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c. A method wherein a deviation of said combined score value compared to a pre-established reference value is identified, indicating that said biomarker signature can be used to predict response to anti-HER2 therapy in patients with HER2+ breast cancer or to classify patients into responder or non-responder patients to anti-HER2 therapy.

9. a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c) An in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying a patient as a responder or non-responder to anti-HER2 therapy according to claim 8, wherein a deviation of the combined score value compared to a pre-established reference value is identified, which indicates a response to anti-HER2 therapy in the patient suffering from HER2+ breast cancer.

10. a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; wherein the ratio is i. combining a first gene in an immune signature with a second gene in a luminal differentiation signature; or ii. combining a first gene included in a tumor cell proliferation signature with a second gene included in a luminal differentiation signature; or iii. Combining a first gene in a HER2 amplicon signature with a second gene in an immune signature; or iv. combining a first gene in the HER2 amplicon signature with a second gene in the tumor cell proliferation signature; or v. Combining a first gene in the HER2 amplicon signature with a second gene in the luminal differentiation signature; or vi. A combination of a first gene included in an immune signature selected from the group consisting of IGKC, IGL, or LAX1 and a second gene included in an immune signature selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17; or vii. A combination of a first gene included in a luminal differentiation signature selected from the group consisting of AFF3, BCL2, or DNAJC12 and a second gene included in a luminal differentiation signature selected from the group consisting of ESR1 or AGR3; or viii. Combining a first gene ASPM included in the tumor cell proliferation signature with a second gene NEK2 included in the tumor cell proliferation signature; where: c. the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and the HER2 amplicon signature comprises a gene (ERBB2, GRB7, STARD3, or TCAP), and d. The in vitro method of predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying a patient as a responder or non-responder to anti-HER2 therapy according to claim 8 or 9, wherein a deviation of the combined score value compared to a pre-established reference value indicates that the patient suffering from HER2+ breast cancer may be responsive to anti-HER2 therapy.

11. a. measuring the expression level of at least two genes selected from the gene combinations of Table 9A in a biological sample obtained from said patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c) An in vitro method of predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying a patient as a responder or non-responder to anti-HER2 therapy according to any one of claims 8 to 10, wherein an identification of a deviation of said combined score value compared to a pre-established reference value indicates that said patient suffering from HER2+ breast cancer may be responsive to anti-HER2 therapy.

12. a. measuring the expression levels of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; wherein the ratio is i. combining a first gene included in the luminal differentiation signature with a second gene included in the immune signature; or ii. combining a first gene included in a luminal differentiation signature with a second gene included in a tumor cell proliferation signature; or iii. Combining a first gene included in the immune differentiation signature with a second gene included in the HER2 amplicon signature; or iv. combining a first gene included in a tumor cell proliferation signature with a second gene included in a HER2 amplicon signature; or v. Combining a first gene in the luminal differentiation signature with a second gene in the HER2 amplicon signature; or vi. A combination of a first gene included in an immune signature selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17 and a second gene included in an immune signature selected from the group consisting of IGKC, IGL, or LAX1; or vii. A combination of a first gene included in a luminal differentiation signature selected from the group consisting of ESR1 or AGR3 and a second gene included in a luminal differentiation signature selected from the group consisting of AFF3, BCL2, or DNAJC12; or viii. Combining a first gene, NEK2, included in the tumor cell proliferation signature with a second gene, ASPM, included in the tumor cell proliferation signature; where: c. the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and the HER2 amplicon signature comprises a gene (ERBB2, GRB7, STARD3, or TCAP), and d. The in vitro method of predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying a patient as a responder or non-responder to anti-HER2 therapy according to claim 8 or 9, wherein a deviation of the combined score value compared to a pre-established reference value indicates that the patient suffering from HER2+ breast cancer may not respond to anti-HER2 therapy.

13. a. measuring the expression level of at least two genes selected from the gene combinations of Table 9B in a biological sample obtained from the patient; b. determining a combination score value by calculating the ratio of expression of the two genes; where c) An in vitro method for predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer or classifying a patient as a responder or non-responder to anti-HER2 therapy according to any one of claims 8, 9 and 12, wherein a deviation of said combined score value compared to a pre-established reference value is indicative that said patient suffering from HER2+ breast cancer may not respond to anti-HER2 therapy.

14. 14. An in vitro method of predicting response to anti-HER2 therapy in a patient suffering from HER2+ breast cancer according to any one of claims 8 to 13, or classifying the patient as a responder or non-responder to anti-HER2 therapy, comprising measuring the expression levels of a group of genes consisting only of: (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and TCAP).

15. 15. The in vitro method according to any one of claims 1 to 14, further comprising identifying the nodal status (pN1) and / or the tumor staging (pT2-4), wherein identifying a nodal status N1-3 and / or a tumor status T2-4 is indicative of a poor prognosis or that said patient is a non-responder to anti-HER2 therapy.

16. The in vitro method of any one of claims 1 to 15, wherein the patient suffers from HER2+ breast cancer.

17. The in vitro method according to any one of claims 1 to 16, wherein the sample is selected from tissue, blood, serum or plasma.

18. 18. The in vitro method of any one of claims 1 to 17, wherein the anti-HER2 therapy is a drug selected from trastuzumab, pertuzumab, lapatinib, pyrotinib, poziotinib, tucatinib, neratinib, trastuzumab deruxtecan, SYD985, or ado-trastuzumab emtansine.

19. 1. In vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) to identify a biomarker signature prognostic for patients with HER2+ breast cancer.

20. 20. The in vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1) according to claim 19 for prognosticating a patient suffering from HER2+ breast cancer.

21. 21. The method of claim 19 or 20, for prognosing a patient suffering from HER2+ breast cancer, comprising administering to the patient an in vivo assay of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1). In vitro use, a first gene is included in the immune signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the immune signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the luminal differentiation signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the immune signature and is selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL, and a second gene is included in the immune signature, and CD2 and the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1).

22. 22. In vitro use of at least two genes selected from the gene combinations of Table 7A according to any one of claims 19 to 21 for prognosticating patients suffering from HER2+ breast cancer.

23. 21. The method of claim 19 or 20, for prognosing a patient suffering from HER2+ breast cancer, comprising administering to the patient an in vivo assay of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, or ESR1). In vitro use, wherein a first gene is included in a tumor cell proliferation signature and a second gene is included in an immune signature, or a first gene is included in a luminal differentiation signature and a second gene is included in an immune signature, or a first gene is included in a tumor cell proliferation signature and a second gene is included in a luminal differentiation signature, or a first gene is included in an immune signature, which is selected from the group consisting of CD27, CXCL8, HLA-C, IGLV3-25, IL2RG, LAX1, NTN3, PIM2, or POU2AF1, and a second gene is included in an immune signature. wherein the immune signature comprises a gene selected from the group consisting of CD79A, CD27, IGJ, POU2AF1, TNFRSF17, IL2RG, PIM2, or IGL, and wherein the immune signature comprises a gene (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17), the tumor cell proliferation signature comprises a gene (EXO1, ASPM, NEK2, or KIF23), and the luminal differentiation signature comprises a gene (BCL2, DNAJC12, AGR3, AFF3, or ESR1).

24. 27. In vitro use of at least two genes selected from the gene combination of Table 7B according to any one of claims 19 or 20 and 23 for prognosticating a patient suffering from HER2+ breast cancer.

25. 25. In vitro use of a group of genes consisting only of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, and ESR1) according to any one of claims 19 to 24 for prognosticating patients suffering from HER2+ breast cancer.

26. 2. In vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) to identify a biomarker signature that predicts response to anti-HER2 therapy in patients with HER2+ breast cancer or classifies patients as responders or non-responders to anti-HER2 therapy.

27. 27. The in vitro use of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) according to claim 26 for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

28. 28. The method of claim 26 or 27, comprising the step of detecting in vivo expression of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) for predicting the response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responder or non-responder patients to anti-HER2 therapy.In vitro use, a first gene is included in the immune signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the tumor cell proliferation signature and a second gene is included in the luminal differentiation signature, or a first gene is included in the HER2 amplicon signature and a second gene is included in the immune signature, or a first gene is included in the HER2 amplicon signature and a second gene is included in the tumor cell proliferation signature. or a first gene is included in a HER2 amplicon signature and a second gene is included in a luminal differentiation signature, or a first gene is included in an immune signature, which is selected from the group consisting of IGKC, IGL, or LAX1, and a second gene is included in an immune signature, which is selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17, or The first gene is included in the luminal differentiation signature, which is selected from the group consisting of AFF3, BCL2, or DNAJC12, and the second gene is included in the luminal differentiation signature, which is selected from the group consisting of ESR1 or AGR3, or the first gene is ASPM included in the tumor cell proliferation signature, and the second gene is NEK2 included in the tumor cell proliferation signature, and the immune signature is a combination of genes (CD27, CD79A, HLA-C, IGJ, IGKC, the tumor cell proliferation signature comprises genes (EXO1, ASPM, NEK2, or KIF23), the luminal differentiation signature comprises genes (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and the HER2 amplicon signature comprises genes (ERBB2, GRB7, STARD3, or TCAP).

29. 29. In vitro use of at least two genes selected from the gene combinations of Table 9A according to any one of claims 26 to 28 for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responder or non-responder patients to anti-HER2 therapy.

30. 28. The method of claim 26 or 27, comprising the step of detecting in vivo expression of at least two genes selected from the group consisting of (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, or TCAP) for predicting the response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responder or non-responder patients to anti-HER2 therapy.In vitro use, a first gene is included in the luminal differentiation signature and a second gene is included in the immune signature, or a first gene is included in the luminal differentiation signature and a second gene is included in the tumor cell proliferation signature, or a first gene is included in the immune signature and a second gene is included in the HER2 amplicon signature, or a first gene is included in the tumor cell proliferation signature and a second gene is included in the HER2 amplicon signature. or a first gene is included in a luminal differentiation signature and a second gene is included in a HER2 amplicon signature, or a first gene is included in an immune signature, which is selected from the group consisting of HLA-C, CD27, IGJ, LAX1, NTN3, PIM2, POU2AF1, or TNFRSF17, and a second gene is included in an immune signature, which is selected from the group consisting of IGKC, IGL, or LAX1, or The first gene is included in the luminal differentiation signature, which is selected from the group consisting of ESR1 or AGR3, and the second gene is included in the luminal differentiation signature, which is selected from the group consisting of AFF3, BCL2, or DNAJC12; or the first gene is NEK2 included in the tumor cell proliferation signature, and the second gene is ASPM included in the tumor cell proliferation signature, and the immune signature is a combination of genes (CD27, CD79A, HLA-C, IGJ, IGKC, the tumor cell proliferation signature comprises genes (EXO1, ASPM, NEK2, or KIF23), the luminal differentiation signature comprises genes (BCL2, DNAJC12, AGR3, AFF3, or ESR1), and the HER2 amplicon signature comprises genes (ERBB2, GRB7, STARD3, or TCAP).

31. 31. In vitro use of at least two genes selected from the combination of genes of Table 9B according to any one of claims 26 or 27 and claim 30 for predicting response to anti-HER2 therapy in patients with HER2+ breast cancer or for classifying patients into responder or non-responder patients to anti-HER2 therapy.

32. 32. In vitro use of a group of genes consisting of only (CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1, TNFRSF17, EXO1, ASPM, NEK2, KIF23, BCL2, DNAJC12, AGR3, AFF3, ESR1, ERBB2, GRB7, STARD3, and TCAP) according to any one of claims 26 to 31 for predicting response to anti-HER2 therapy in patients suffering from HER2+ breast cancer or for classifying patients into responders or non-responders to anti-HER2 therapy.

33. 19. An anti-HER2 therapeutic agent or any pharmaceutical composition comprising same, optionally with a pharma- ceutically acceptable excipient or carrier, for use in the treatment of a patient suffering from HER2+ breast cancer, said method comprising predicting the response to anti-HER2 therapy in said patient suffering from HER2+ breast cancer, or classifying the patient as a responder or non-responder to anti-HER2 therapy, by following the method of any one of claims 8 to 18.

34. 34. The anti-HER2 therapeutic agent, or any pharmaceutical composition comprising same, optionally with a pharma- ceutically acceptable excipient or carrier, for use in the treatment of patients with HER2+ breast cancer according to claim 33, wherein said anti-HER2 therapeutic agent is optionally selected from trastuzumab, pertuzumab, lapatinib, pyrotinib, poziotinib, tucatinib, neratinib, trastuzumab deruxtecan, SYD985, or ado-trastuzumab emtansine.